Meta-Analysis| Volume 54, ISSUE 2, P183-191, February 2022

Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies



      Several observational studies on Tofacitinib (TOFA) in ulcerative colitis (UC) have been published over the last 2 years.


      To estimate effectiveness and safety of TOFA arising from real-world experience.


      PubMed Central/Medline and Embase were systematically searched for real-world observational studies on TOFA for the treatment of UC through November 2020.


      Seven studies comprising 759 patients met the inclusion criteria. The pooled estimate rates were 49% for clinical response, 40% for clinical remission, and 34% for corticosteroid-free clinical remission at induction, while the rates of endoscopic response and endoscopic remission were 37% and 19%, respectively. At maintenance, the pooled estimate rates of clinical response, clinical remission, and corticosteroid-free clinical remission were 36%, 35%, and 24%, respectively. The pooled estimate of incidence rate of adverse events was 53.0 per 100 person-years (PY), while the pooled estimate of incidence rate of withdrawal of TOFA due to adverse events was 9.3 per 100 PY, with a pooled rate of infections of 17.6 per 100 PY.


      Cumulative analysis of data from real-world studies confirmed the good efficacy of TOFA in UC shown by randomized controlled trials for both induction and maintenance, while the safety profile was consistent with previous reports.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Macaluso FS
        • Renna S
        • Orlando A
        • et al.
        The biologics of ulcerative colitis.
        Expert Opin Biol Ther. 2017; 17: 175-184
        • Macaluso FS
        • Orlando R
        • Fries W
        • et al.
        The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
        Dig Liver Dis. 2018; 50: 675-681
        • Macaluso FS
        • Maida M
        • Ventimiglia M
        • et al.
        Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies.
        Expert Opin Biol Ther. 2020; 20: 193-203
        • Olivera P
        • Danese S
        • Peyrin-Biroulet L.
        Next generation of small molecules in inflammatory bowel disease.
        Gut. 2017; 66: 199-209
        • Macaluso FS
        • Rodríguez-Lago I.JAK
        Inhibition as a therapeutic strategy for inflammatory bowel disease.
        Curr Drug Metab. 2020; 21: 247-255
        • Sandborn WJ
        • Su C
        • Sands BE
        • et al.
        Tofacitinib as induction and maintenance therapy for ulcerative colitis.
        N Engl J Med. 2017; 376: 1723-1736
        • Ha C
        • Ullman TA
        • Siegel CA
        • et al.
        Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population.
        Clin Gastroenterol Hepatol. 2012; 10: 1002-1007
        • Stroup DF
        • Berlin JA
        • Morton SC
        • et al.
        Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group.
        JAMA. 2000; 283: 2008-2012
        • Lair-Mehiri L
        • Stefanescu C
        • Vaysse T
        • et al.
        Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
        Dig Liver Dis. 2020; 52: 268-273
        • Weisshof R
        • Aharoni Golan M
        • et al.
        Real-world experience with tofacitinib in IBD at a tertiary center.
        Dig Dis Sci. 2019; 64: 1945-1951
        • Honap S
        • Chee D
        • Chapman TP
        • et al.
        Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience.
        J Crohns Colitis. 2020; 14: 1385-1393
        • Deepak P
        • Alayo QA
        • Khatiwada A
        • et al.
        Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis.
        Clin Gastroenterol Hepatol. 2020:; (S1542-3565(20)30913-7. Epub ahead of print)
        • Hoffmann P
        • Globig AM
        • Thomann AK
        • et al.
        Tofacitinib in treatment-refractory moderate to severe ulcerative colitis: real-world experience from a retrospective multicenter observational study.
        J Clin Med. 2020; 9: 2177
        • Chaparro M
        • Garre A
        • Mesonero F
        • et al.
        Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry.
        J Crohns Colitis. 2021; 15: 35-42
        • Biemans VBC
        • Sleutjes JAM
        • de Vries AC
        • et al.
        Dutch initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch initiative on Crohn and Colitis (ICC) registry.
        Aliment Pharmacol Ther. 2020; 51: 880-888
      1. National Institute for Clinical Excellence. Appendix 4. Quality assessment for Case series. Available at: (accessed date: January 2021).

        • Der Simonian R
        • Laird N.
        Meta-analysis in clinical trials.
        Control Clin Trials. 1986; 7: 177-188
        • Higgins JP
        • Thompson SG
        • Deeks JJ
        • et al.
        Measuring inconsistency in meta-analyses.
        BMJ. 2003; 327: 557-560
        • Wan X
        • Wang W
        • Liu J
        • et al.
        Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range.
        BMC Med Res Methodol. 2014; 14: 135
      2. R Core Team (2016). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL

        • Macaluso FS
        • Maida M
        • Ventimiglia M
        • et al.
        Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small molecule drugs in ulcerative colitis: a meta-analysis.
        Inflamm Bowel Dis. 2019; 25: 987-997
        • Taxonera C
        • Olivares D
        • Alba C.
        Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis.
        Inflamm Bowel Dis. 2021; (Epub ahead of print. PMID: 33586766)
        • Ware JH
        • Hamel MB.
        Pragmatic trials—guides to better patient care?.
        N Engl J Med. 2011; 364: 1685-1687